Condition
Cardiooncology
Total Trials
6
Recruiting
2
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 6 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
1Total
Not Applicable (1)
Trial Status
Unknown3
Recruiting2
Not Yet Recruiting1
Clinical Trials (6)
Showing 6 of 6 trials
NCT06930521Not ApplicableNot Yet Recruiting
JUdicious Surveillance for Trastuzumab Induced Cardiotoxicity in the First Year
NCT06309862RecruitingPrimary
Immune Checkpoint Inhibitor Therapy for Cancer and Risk of Myocarditis or Cardiomyopathy
NCT06302634RecruitingPrimary
Cardio-Oncology Rehabilitation Care Process
NCT05150080UnknownPrimary
Early Identification and Evaluation of Cyclophosphamide Cardiotoxicity
NCT03678337UnknownPrimary
Prevention and Pharmacological Management of Cardiac Adverse Drug Reactions Induced by Drugs Used in Oncology.
NCT03776331UnknownPrimary
Vascular Functions in Myeloma Patients During Anti-tumor Therapy
Showing all 6 trials